Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q1 2018 call → NOWe need to determine if management conveys that the business is currently outgrowing the company's own size, i.e., that current activity/demand/commitments are large relative to the smallness of the company. The transcript shows strong growth, but does management explicitly or implicitly convey that the company is small and what's happening is disproportionately large? Key points: Revenue $782M, up 31%. They talk about strong demand, consumables growth, NovaSeq rollout, microarray growth, etc. They mention "we're in the earliest stages of the genomics journey" and "only just beginning to see how Illumina and our customers will inform and transform patient lives." That suggests they see themselves as early, but does that mean the current business is small relative to what's arriving? They talk about the opportunity being huge, but they also have a large revenue base. They mention "the opportunity for Illumina and our customers in the next 20 years looks even more exciting." That's forward-looking. They also mention "we're only just beginning" but that's about the journey, not necessarily that current demand is disproportionately large relative to their size. They do mention that they are seeing strong growth, but they don't explicitly say "we are small and this is huge relative to us." They talk about the market being large, but that's generic. They also mention that they are investing in programs to support adoption, but that's not about current scale. The question asks: "Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup?" That is, is there a disproportion between the size of the company and the size of what is currently arriving? Looking for phrases like "we are small" or "this is large relative to us" or "we can't keep up" or "this single customer is as big as our whole company" etc. I don't see that. They report strong growth but that's normal. They also mention that they are increasing guidance, but that's not about disproportion. They do mention that they are seeing "strong demand" and "record" results, but that's typical. They also mention that they are investing in R&D and commercial projects to capitalize on momentum, but that's not about being small.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.